GIMEMA LAL2116, D-ALBA, Updated Results and Prognostic Impact of IKZF1 in Ph+ ALL

Author(s):

Jorge E. Cortes, MD, MD Anderson Cancer Center,Robin Foa, MD, Sapienza University

Robin Foà, MD, leads a discussion on the primary takeaways from the GIMEMA LAL2116, D-ALBA trial, particularly the prognostic impact of the IKZF1-plus genotype and the Ikaros mutation.

EP: 1.OPTIC Primary Analysis: a Dose-Optimization Study of 3 Starting Doses of Ponatinib in CML Treatment

EP: 2.Phase II Results: Ponatinib + Blinatumomab in Ph+ ALL

Now Viewing

EP: 3.GIMEMA LAL2116, D-ALBA, Updated Results and Prognostic Impact of IKZF1 in Ph+ ALL

EP: 4.GIMEMA LALl2317: Sequential Chemotherapy and Blinatumomab for Adult ALL

EP: 5.MRD as a Prognostic Indicator in Children and Young Adults with Very High-Risk ALL

Data from the following presentations are discussed:

Updated results of the, D-ALBA trial, for newly diagnosed adults with Ph+ ALL. (Chiaretti, EHA 2021 S112)
- Efficacy: In the updated 2-year follow-up from the GIMEMA LAL2116 trial, molecular responses to treatment with dasatinib and blinatumomab were noted in the majority of enrolled patients. An overall survival (OS) and disease-free survival (DFS) of 87.8% and was 79.8%, respectively was observed. Notably, a greater DFS rate was demonstrated in patients achieving a molecular response upon induction/consolidation treatment compared to those who did not (100% vs 75.9%, respectively; p=0.028). Furthermore, a greater DFS benefit was noted in those patients with an IKZF1-plus genotype.
- Safety: A high incidence of CNS (central nervous system) involvement wasrecorded in addition to 3 relapses. Additionally, 3 deaths in CHR (complete hematologic remission) were documented.